BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cook M, Chauhan A. Clinical Application of Oncolytic Viruses: A Systematic Review. Int J Mol Sci 2020;21:E7505. [PMID: 33053757 DOI: 10.3390/ijms21207505] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 11.5] [Reference Citation Analysis]
Number Citing Articles
1 Silk AW, O’day SJ, Kaufman HL, Bryan J, Norrell JT, Imbergamo C, Portal D, Zambrano-acosta E, Palmeri M, Fein S, Wu C, Guerreiro L, Medina D, Bommareddy PK, Zloza A, Fox BA, Ballesteros-merino C, Ren Y, Shafren D, Grose M, Vieth JA, Mehnert JM. A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study. Cancer Immunol Immunother 2022. [DOI: 10.1007/s00262-022-03314-1] [Reference Citation Analysis]
2 Kong D, Yang Z, Li G, Wu Q, Gu Z, Wan D, Zhang Q, Zhang X, Cheng S, Liu B, Zhang K, Zhang W. SIRPα antibody combined with oncolytic virus OH2 protects against tumours by activating innate immunity and reprogramming the tumour immune microenvironment. BMC Med 2022;20:376. [PMID: 36310169 DOI: 10.1186/s12916-022-02574-z] [Reference Citation Analysis]
3 Li Z, Feiyue Z, Gaofeng L, Haifeng L. Lung cancer and oncolytic virotherapy--enemy's enemy. Transl Oncol 2022;27:101563. [PMID: 36244134 DOI: 10.1016/j.tranon.2022.101563] [Reference Citation Analysis]
4 Bifulco M, Di Zazzo E, Napolitano F, Malfitano AM, Portella G. History of how viruses can fight cancer: From the miraculous healings to the approval of oncolytic viruses. Biochimie 2022. [DOI: 10.1016/j.biochi.2022.10.008] [Reference Citation Analysis]
5 Corbett V, Hallenbeck P, Rychahou P, Chauhan A. Evolving role of seneca valley virus and its biomarker TEM8/ANTXR1 in cancer therapeutics. Front Mol Biosci 2022;9:930207. [DOI: 10.3389/fmolb.2022.930207] [Reference Citation Analysis]
6 Garmaroudi GA, Karimi F, Naeini LG, Kokabian P, Givtaj N, Rehman MU. Therapeutic Efficacy of Oncolytic Viruses in Fighting Cancer: Recent Advances and Perspective. Oxidative Medicine and Cellular Longevity 2022;2022:1-14. [DOI: 10.1155/2022/3142306] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Li Q, Oduro PK, Guo R, Li R, Leng L, Kong X, Wang Q, Yang L. Oncolytic Viruses: Immunotherapy Drugs for Gastrointestinal Malignant Tumors. Front Cell Infect Microbiol 2022;12:921534. [DOI: 10.3389/fcimb.2022.921534] [Reference Citation Analysis]
8 van Vloten JP, Matuszewska K, Minow MAA, Minott JA, Santry LA, Pereira M, Stegelmeier AA, McAusland TM, Klafuric EM, Karimi K, Colasanti J, McFadden DG, Petrik JJ, Bridle BW, Wootton SK. Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer. J Immunother Cancer 2022;10:e004335. [PMID: 35296558 DOI: 10.1136/jitc-2021-004335] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Naumenko VA, Stepanenko AA, Lipatova AV, Vishnevskiy DA, Chekhonin VP. Infection of non-cancer cells: A barrier or support for oncolytic virotherapy? Molecular Therapy - Oncolytics 2022;24:663-82. [DOI: 10.1016/j.omto.2022.02.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
10 Blitz SE, Kappel AD, Gessler FA, Klinger NV, Arnaout O, Lu Y, Peruzzi PP, Smith TR, Chiocca EA, Friedman GK, Bernstock JD. Tumor-Associated Macrophages/Microglia in Glioblastoma Oncolytic Virotherapy: A Double-Edged Sword. Int J Mol Sci 2022;23:1808. [PMID: 35163730 DOI: 10.3390/ijms23031808] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Makuku R, Seyedmirzaei H, Tantuoyir MM, Rodríguez-Román E, Albahash A, Mohamed K, Moyo E, Ahmed AO, Razi S, Rezaei N. Exploring the application of immunotherapy against HIV infection in the setting of malignancy: A detailed review article. Int Immunopharmacol 2022;105:108580. [PMID: 35121225 DOI: 10.1016/j.intimp.2022.108580] [Reference Citation Analysis]
12 Cristi F, Gutiérrez T, Hitt MM, Shmulevitz M. Genetic Modifications That Expand Oncolytic Virus Potency. Front Mol Biosci 2022;9:831091. [DOI: 10.3389/fmolb.2022.831091] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Bhatt DK, Wekema L, Carvalho Barros LR, Chammas R, Daemen T. A systematic analysis on the clinical safety and efficacy of onco-virotherapy. Mol Ther Oncolytics 2021;23:239-53. [PMID: 34761104 DOI: 10.1016/j.omto.2021.09.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
14 Roesch A, Zölls S, Stadler D, Helbig C, Wuchner K, Kersten G, Hawe A, Jiskoot W, Menzen T. Particles in Biopharmaceutical Formulations, Part 2: An Update on Analytical Techniques and Applications for Therapeutic Proteins, Viruses, Vaccines and Cells. J Pharm Sci 2021:S0022-3549(21)00689-4. [PMID: 34919969 DOI: 10.1016/j.xphs.2021.12.011] [Reference Citation Analysis]
15 Cook J, Acosta-Medina AA, Peng KW, Lacy M, Russell S. Oncolytic virotherapy - Forging its place in the immunomodulatory paradigm for Multiple Myeloma. Cancer Treat Res Commun 2021;29:100473. [PMID: 34673439 DOI: 10.1016/j.ctarc.2021.100473] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Hofman L, Lawler SE, Lamfers MLM. The Multifaceted Role of Macrophages in Oncolytic Virotherapy. Viruses 2021;13:1570. [PMID: 34452439 DOI: 10.3390/v13081570] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
17 Malogolovkin A, Gasanov N, Egorov A, Weener M, Ivanov R, Karabelsky A. Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes. Viruses 2021;13:1271. [PMID: 34209981 DOI: 10.3390/v13071271] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
18 Ma XY, Hill BD, Hoang T, Wen F. Virus-inspired strategies for cancer therapy. Semin Cancer Biol 2021:S1044-579X(21)00191-7. [PMID: 34182141 DOI: 10.1016/j.semcancer.2021.06.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
19 Abd-Aziz N, Poh CL. Development of oncolytic viruses for cancer therapy. Transl Res 2021:S1931-5244(21)00104-3. [PMID: 33905949 DOI: 10.1016/j.trsl.2021.04.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
20 Heidbuechel JPW, Engeland CE. Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies. J Hematol Oncol 2021;14:63. [PMID: 33863363 DOI: 10.1186/s13045-021-01075-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 19.0] [Reference Citation Analysis]
21 Jin KT, Du WL, Liu YY, Lan HR, Si JX, Mou XZ. Oncolytic Virotherapy in Solid Tumors: The Challenges and Achievements. Cancers (Basel) 2021;13:588. [PMID: 33546172 DOI: 10.3390/cancers13040588] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
22 Song K, Viskovska M. Design and Engineering of Deimmunized Vaccinia Viral Vectors. Biomedicines 2020;8:E491. [PMID: 33187060 DOI: 10.3390/biomedicines8110491] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
23 Menotti L, Avitabile E. Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy.Int J Mol Sci. 2020;21. [PMID: 33167582 DOI: 10.3390/ijms21218310] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]